Elevance Health, Inc. $ELV Holdings Trimmed by Hsbc Holdings PLC

Hsbc Holdings PLC lowered its holdings in Elevance Health, Inc. (NYSE:ELV) by 0.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 506,504 shares of the company’s stock after selling 3,462 shares during the period. Hsbc Holdings PLC’s holdings in Elevance Health were worth $177,578,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Murphy Middleton Hinkle & Parker Inc. acquired a new stake in Elevance Health during the fourth quarter valued at $5,941,000. Bright Rock Capital Management LLC acquired a new position in Elevance Health in the 4th quarter worth about $7,362,000. Prana Capital Management LP raised its stake in shares of Elevance Health by 798.9% during the 3rd quarter. Prana Capital Management LP now owns 51,633 shares of the company’s stock worth $16,684,000 after purchasing an additional 45,889 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new stake in shares of Elevance Health during the 3rd quarter worth about $10,047,000. Finally, Loews Corp lifted its holdings in shares of Elevance Health by 107.5% during the 3rd quarter. Loews Corp now owns 110,000 shares of the company’s stock valued at $35,543,000 after buying an additional 57,000 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Insider Transactions at Elevance Health

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the transaction, the director owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.34% of the company’s stock.

Elevance Health Price Performance

NYSE ELV opened at $416.97 on Friday. The stock has a 50-day simple moving average of $391.29 and a 200 day simple moving average of $351.14. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $427.19. The stock has a market capitalization of $90.55 billion, a PE ratio of 17.74, a P/E/G ratio of 2.37 and a beta of 0.67. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The firm had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company’s revenue was up 1.5% on a year-over-year basis. During the same quarter last year, the firm posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Research analysts anticipate that Elevance Health, Inc. will post 26.86 EPS for the current year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th were paid a $1.72 dividend. The ex-dividend date was Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. Elevance Health’s dividend payout ratio (DPR) is presently 29.26%.

Wall Street Analysts Forecast Growth

ELV has been the topic of a number of research reports. Weiss Ratings upgraded Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, May 18th. Deutsche Bank Aktiengesellschaft upgraded shares of Elevance Health from a “hold” rating to a “buy” rating and lifted their target price for the company from $363.00 to $498.00 in a research note on Wednesday, May 20th. Truist Financial boosted their target price on shares of Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. Bank of America increased their price target on shares of Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a research note on Thursday, June 4th. Finally, Barclays raised their price target on shares of Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a report on Tuesday, May 26th. Fourteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $419.16.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.